🔗 Share this article

A daily weight loss pill may help individuals cut their body weight by up to a fifth, as per a trial that could pave the way for countless people additional people to lose weight.

How the Drug Works

The drug, called orforglipron, targets the same GLP-1 pathways as slimming injections like Mounjaro and semaglutide. In a trial of 3,127 participants, 20% of users who took the once-a-day pill for 72 weeks lost 20% or more of their total weight.

Weight loss injections have been revolutionary, but oral forms represent a holy grail since they are easier to store, distribute and take, and may also be projected to be cheaper, providing fresh hope for millions trying to lose weight.

The medication is a GLP-1 stimulant, a type of medication that helps reducing blood sugar levels, slows the digestion of food and can curb appetite.

Trial Findings and Accessibility

The weight loss seen in participants taking the tablet are less dramatic as that in users taking injectable alternatives, but experts believe the oral form will be easier to obtain and convenient than shots.

Orforglipron is not yet authorized by the US Food and Drug Administration or regulators in additional nations. The manufacturer stated it anticipates substantial interest when the new pill is released.

In the study, the over three thousand patients were split into cohorts taking the medication tablets of varying strengths, whereas some received a dummy pill, for the trial period.

Each of the patients were diagnosed with excess weight, indicating they had a body mass index score of 30 or higher, but they were free from high blood sugar. Participants from several nations took part in the research.

Key Results

Scientists found that following 72 weeks users on the smallest amount lost an average of nearly 8% of their weight. Those on the highest dose lost an mean of over 11% of their body weight.

In patients using the strongest tablets, more than half had a decrease of 10% or more of body weight, 36% had a loss of 15% or more, and 18.4% had a reduction of 20% or higher.

Researchers said additional health metrics also got better among people taking the medication, such as improved blood pressure, a reduced waist size and a reduction in LDL levels.

Frequent side-effects were stomach-related, which were said to be mild to moderate.

“Among participants with obesity, 72-week treatment with orforglipron led to notable decreases in weight than placebo,” researchers noted.

Potential Impact

Medical leaders have hailed slimming treatments as game-changing. However injections involve additional logistical efforts for health services, so oral options could help many additional people trying to lose weight.

Separate studies shows slimming injections could be successful on minors starting from age six who are obese or have diabetes. However, digestive issues were reported more frequently among children taking the medications.

They said that longer follow-up durations in future trials and more real-world research were crucial to determine the long-term effects.”